Jonathan J Chen1, Alexander Stessin2, Paul Christos3, A Gabriella Wernicke2, Dattatreyudu Nori2, Bhupesh Parashar2. 1. Weill Cornell/Sloan-Kettering/Rockefeller Tri-Institutional MD-PhD Program, New York, New York, U.S.A. 2. Stich Radiation Center, New York Presbyterian Hospital/Weill Cornell Medical Center, New York, New York, U.S.A. 3. Division of Biostatistics and Epidemiology, Weill Cornell Medical College, New York, New York, U.S.A.
Abstract
OBJECTIVE: The purpose of this study was to investigate and compare the cause-specific survival (CSS) of stage I (tumor [T]1 node [N]0 metastasis [M]0) versus stage II (T2N0M0) glottic cancer in a large population cohort. STUDY DESIGN: We analyzed data from the Surveillance, Epidemiology, and End Results 18 database from 1973 to 2009, comprising patients diagnosed with T1N0M0 or T2N0M0 squamous cell glottic cancer. Kaplan-Meier survival analysis, multivariable Cox proportional hazards regression analysis, and competing-risks survival regression were used for statistical analysis. RESULTS: There were 4,422 patients who met all inclusion criteria. The 36-month CSS was 93.9% for stage I verus 86.5% for stage II, with P < 0.0001. Stage II status conferred a 2.494 hazard ratio for increased risk of cause-specific death compared to stage I. CONCLUSIONS: Stage II glottic cancers have a significantly worse prognosis and may need a different approach to management than stage I tumors. LEVEL OF EVIDENCE: 4.
OBJECTIVE: The purpose of this study was to investigate and compare the cause-specific survival (CSS) of stage I (tumor [T]1 node [N]0 metastasis [M]0) versus stage II (T2N0M0) glottic cancer in a large population cohort. STUDY DESIGN: We analyzed data from the Surveillance, Epidemiology, and End Results 18 database from 1973 to 2009, comprising patients diagnosed with T1N0M0 or T2N0M0 squamous cell glottic cancer. Kaplan-Meier survival analysis, multivariable Cox proportional hazards regression analysis, and competing-risks survival regression were used for statistical analysis. RESULTS: There were 4,422 patients who met all inclusion criteria. The 36-month CSS was 93.9% for stage I verus 86.5% for stage II, with P < 0.0001. Stage II status conferred a 2.494 hazard ratio for increased risk of cause-specific death compared to stage I. CONCLUSIONS: Stage II glottic cancers have a significantly worse prognosis and may need a different approach to management than stage I tumors. LEVEL OF EVIDENCE: 4.
Authors: Mohamed Shelan; Lukas Anschuetz; Adrian D Schubert; Beat Bojaxhiu; Alan Dal Pra; Frank Behrensmeier; Daniel M Aebersold; Roland Giger; Olgun Elicin Journal: Strahlenther Onkol Date: 2017-05-04 Impact factor: 3.621
Authors: Danielle L Gainor; Emily Marchiano; Emily Bellile; Matthew E Spector; Jeremy M G Taylor; Gregory T Wolf; Norman D Hogikyan; Mark E Prince; Carol R Bradford; Avraham Eisbruch; Francis Worden; Andrew G Shuman Journal: Otolaryngol Head Neck Surg Date: 2017-06-13 Impact factor: 3.497